SCIENTURE HOLDINGS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
SCIENTURE HOLDINGS, INC. (SCNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 20.00 thousand shares for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-04-26.
Discontinued › Shareholders' Equity › Shares Granted or Issued, Share-Based Payment Arrangement
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2021-04-26
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-03-31 was 20.00K shares, a 20.00% increase year-over-year.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-12-31 was 0.00 shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-09-30 was 15.38K shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2020-06-30 was 62.10K shares.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 94.15K shares, a 11.85% increase from fiscal 2019.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2019 was 84.18K shares, a 9.88% decline from fiscal 2018.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2018 was 93.41K shares, a 64.60% decline from fiscal 2017.
- SCIENTURE HOLDINGS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2017 was 263.85K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-03-31 | 20.00K shares 10-Q · filed 2021-04-26 | 20.00K shares derived: sum of 2 quarters · filed 2021-04-26 | 35.38K shares derived: sum of 3 quarters · filed 2021-04-26 | 97.49K shares derived: sum of 4 quarters · filed 2021-04-26 | |||
| 2020-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | 15.38K shares derived: sum of 2 quarters · filed 2021-03-29 | 77.49K shares derived: sum of 3 quarters · filed 2021-03-29 | 94.15K shares 10-K · filed 2021-03-29 | |||
| 2020-09-30 | 15.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-26 | 77.49K shares derived: sum of 2 quarters · filed 2020-10-26 | 94.15K shares 10-Q · filed 2020-10-26 | -326.67K shares derived: sum of 4 quarters · filed 2021-03-29 | |||
| 2020-06-30 | 62.10K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | 78.77K shares 10-Q · filed 2020-07-27 | -342.05K shares derived: sum of 3 quarters · filed 2021-03-29 | -342.05K shares derived: sum of 4 quarters · filed 2021-03-29 | |||
| 2020-03-31 | 16.67K shares 10-Q · filed 2020-05-04 | -404.15K shares derived: sum of 2 quarters · filed 2021-03-29 | -404.15K shares derived: sum of 3 quarters · filed 2021-03-29 | ||||
| 2019-12-31 | -420.82K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -420.82K shares derived: sum of 2 quarters · filed 2021-03-29 | 84.18K shares 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | 505.00K shares 10-Q · filed 2019-10-28 | |||||
| 2019-06-30 | 505.00K shares 10-Q · filed 2019-07-26 | ||||||
| 2019-05-31 | 84.18K shares 10-K · filed 2020-03-30 | 505.00K shares 10-Q · filed 2019-07-26 | |||||
| 2019-04-30 | 84.18K shares 10-K · filed 2021-03-29 | 505.00K shares 10-Q · filed 2019-07-26 | |||||
| 2018-12-31 | 93.41K shares 10-K · filed 2020-03-30 | 560.40K shares 10-K · filed 2019-03-22 | |||||
| 2018-04-30 | 560.40K shares 10-K · filed 2019-03-22 | ||||||
| 2017-12-31 | 263.85K shares 10-K · filed 2019-03-22 | ||||||
| 2017-04-30 | 253.85K shares 10-K · filed 2019-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |